SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.

Bibliographic Details
Main Authors:	Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana
Format:	Article
Language:	English
Published:	Nature Publishing Group 2019-06-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-019-10367-x

id	doaj-63c728d50eef448aa2fdb9117a059704
record_format	Article
spelling	doaj-63c728d50eef448aa2fdb9117a0597042021-05-11T11:23:33ZengNature Publishing GroupNature Communications2041-17232019-06-0110111610.1038/s41467-019-10367-xSHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancersGreg G. Jones0Isabel Boned del Río1Sibel Sari2Aysen Sekerim3Lucy C. Young4Nicole Hartig5Itziar Areso Zubiaur6Mona A. El-Bahrawy7Rob E. Hynds8Winnie Lei9Miriam Molina-Arcas10Julian Downward11Pablo Rodriguez-Viciana12University College London Cancer InstituteUniversity College London Cancer InstituteUniversity College London Cancer InstituteUniversity College London Cancer InstituteUniversity College London Cancer InstituteUniversity College London Cancer InstituteUniversity College London Cancer InstituteDepartment of Histopathology, Imperial College LondonUniversity College London Cancer InstituteUniversity College London Cancer InstituteThe Oncogene Biology Lab, The Francis Crick InstituteThe Oncogene Biology Lab, The Francis Crick InstituteUniversity College London Cancer InstituteTargeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.https://doi.org/10.1038/s41467-019-10367-x
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Greg G. Jones Isabel Boned del Río Sibel Sari Aysen Sekerim Lucy C. Young Nicole Hartig Itziar Areso Zubiaur Mona A. El-Bahrawy Rob E. Hynds Winnie Lei Miriam Molina-Arcas Julian Downward Pablo Rodriguez-Viciana
spellingShingle	Greg G. Jones Isabel Boned del Río Sibel Sari Aysen Sekerim Lucy C. Young Nicole Hartig Itziar Areso Zubiaur Mona A. El-Bahrawy Rob E. Hynds Winnie Lei Miriam Molina-Arcas Julian Downward Pablo Rodriguez-Viciana SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers Nature Communications
author_facet	Greg G. Jones Isabel Boned del Río Sibel Sari Aysen Sekerim Lucy C. Young Nicole Hartig Itziar Areso Zubiaur Mona A. El-Bahrawy Rob E. Hynds Winnie Lei Miriam Molina-Arcas Julian Downward Pablo Rodriguez-Viciana
author_sort	Greg G. Jones
title	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
title_short	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
title_full	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
title_fullStr	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
title_full_unstemmed	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
title_sort	shoc2 phosphatase-dependent raf dimerization mediates resistance to mek inhibition in ras-mutant cancers
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2019-06-01
description	Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.
url	https://doi.org/10.1038/s41467-019-10367-x
work_keys_str_mv	AT greggjones shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT isabelboneddelrio shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT sibelsari shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT aysensekerim shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT lucycyoung shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT nicolehartig shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT itziararesozubiaur shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT monaaelbahrawy shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT robehynds shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT winnielei shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT miriammolinaarcas shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT juliandownward shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers AT pablorodriguezviciana shoc2phosphatasedependentrafdimerizationmediatesresistancetomekinhibitioninrasmutantcancers
_version_	1721446526655397888

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Similar Items